GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » LeMaitre Vascular Inc (NAS:LMAT) » Definitions » Return-on-Tangible-Equity

LeMaitre Vascular (LeMaitre Vascular) Return-on-Tangible-Equity

: 18.32% (As of Dec. 2023)
View and export this data going back to 2006. Start your Free Trial

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. LeMaitre Vascular's annualized net income for the quarter that ended in Dec. 2023 was $33.9 Mil. LeMaitre Vascular's average shareholder tangible equity for the quarter that ended in Dec. 2023 was $184.9 Mil. Therefore, LeMaitre Vascular's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 was 18.32%.

The historical rank and industry rank for LeMaitre Vascular's Return-on-Tangible-Equity or its related term are showing as below:

LMAT' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 9.89   Med: 20.36   Max: 32.39
Current: 17.46

During the past 13 years, LeMaitre Vascular's highest Return-on-Tangible-Equity was 32.39%. The lowest was 9.89%. And the median was 20.36%.

LMAT's Return-on-Tangible-Equity is ranked better than
82.27% of 767 companies
in the Medical Devices & Instruments industry
Industry Median: 1.97 vs LMAT: 17.46

LeMaitre Vascular Return-on-Tangible-Equity Historical Data

The historical data trend for LeMaitre Vascular's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LeMaitre Vascular Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Equity
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.10 32.39 29.37 14.17 17.40

LeMaitre Vascular Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Return-on-Tangible-Equity Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.86 15.17 19.25 16.98 18.32

Competitive Comparison

For the Medical Instruments & Supplies subindustry, LeMaitre Vascular's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LeMaitre Vascular Return-on-Tangible-Equity Distribution

For the Medical Devices & Instruments industry and Healthcare sector, LeMaitre Vascular's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where LeMaitre Vascular's Return-on-Tangible-Equity falls into.



LeMaitre Vascular Return-on-Tangible-Equity Calculation

LeMaitre Vascular's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=30.105/( (155.729+190.244 )/ 2 )
=30.105/172.9865
=17.40 %

LeMaitre Vascular's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=33.86/( (179.493+190.244)/ 2 )
=33.86/184.8685
=18.32 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


LeMaitre Vascular  (NAS:LMAT) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


LeMaitre Vascular Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of LeMaitre Vascular's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


LeMaitre Vascular (LeMaitre Vascular) Business Description

Traded in Other Exchanges
Address
63 Second Avenue, Burlington, MA, USA, 01803
LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are primarily used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes the largest proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.
Executives
George W Lemaitre director, 10 percent owner, officer: Chairman, President and CEO 342 BUNKER HILL STREET, #2B, CHARLESTOWN MA 02129
Bridget A Ross director C/O HENRY SCHEIN, INC., 135 DURYEA ROAD, MELVILLE NY 11747
John A Roush director C/O GSI GROUP INC., 125 MIDDLESEX TURNPIKE, BEDFORD MA 01730-1409
Lawrence J Jasinski director SOTEIRA INC., 14 TECH CIRCLE, NATICK MA 01760
David B Roberts director, officer: CFO and Director 55 BRADFORD STREET, NEEDHAM MA 02492
Trent G Kamke officer: Senior V. P., Operations 61 WILLOWDEAN AVENUE, WEST ROXBURY MA 02132
Martha Shadan director 9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
Pellegrino Joseph P Jr officer: Executive V.P. Finance 68 BEACON STREET, BOSTON MA 02108
Michael H Thomas director P.O. BOX 2207, NOKOMIS FL 34274-2207
Peter R Gebauer officer: President, International OP AM WALDFELD 17, BAD SODEN 2M 65812
Michael T Wijas officer: VP of Sales, The Americas C/O LEMAITRE VASCULAR, INC., 63 SECOND AVENUE, BURLINGTON MA 01803
Lemaitre Cornelia W director, officer: V.P., Human Resources,Director 8 SUNSET ROCK ROAD, ANDOVER MA 01810
Russell D Hays director C/O BIOSOURCE INTERNATIONAL INC, 542 FLYNN RD, CAMARILLO CA 93012
Robert V Linden officer: VP, North American Sales 236 WOODEN BRIDGE ROAD, HOLLAND PA 18966
Thorndike William N Jr director HOUSATONIC PARTNERS, 800 BOYLSTON STREET, SUITE 2220, BOSTON MA 02199